Cork, Ireland (ots/PRNewswire) - Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 ...
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
Cork, Ireland (ots/PRNewswire) - - Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II ...
Cork, Ireland (ots/PRNewswire) - Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens Janssen Sciences Ireland UC and certain Janssen affiliates* today announced it will present thirteen abstracts ...
Cork, Ireland (ots/PRNewswire) - Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) announced 32-week data from an ongoing phase IIb study. A ...
Cork, Ireland (ots/PRNewswire) - Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development ...
Cork, Ireland (ots/PRNewswire) - Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that Phase IIb data studying a combination regimen of ...
Cork, Ireland (ots/PRNewswire) - -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed as Eviplera(R) in the European Union -- Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, ...
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's ...
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) ...